10.06.2025 • NewsIMCDmedical productsLubrizol

IMCD to Grow Lubrizol’s Medical Solutions in North America

Lubrizol, a medical-grade thermoplastic polyurethane (TPU) solutions provider, has expanded its distribution agreement with IMCD to help meet demand for medical solutions in the US and Canada.

The collaboration aims to expand a well-established medical TPU-focused partnership in Europe to North America, with IMCD empowered to enhance market penetration, efficiently manage inventory, and strengthen customer relationships.

Lubrizol has an extensive range of medical-grade TPU solutions and differentiated design, development, and manufacturing services for medical devices. IMCD is a partner for the distribution and formulation of specialty chemicals and ingredients. The company has developed expertise in medical-grade polymers and established an extensive presence in the medical and healthcare market, combining partnerships with leading suppliers and a wide customer base.

“We are delighted to broaden our distribution with IMCD to include North America, as this enables us to continue to be the most trusted partner in the medical device industry, with service levels and the best-in-class materials our customers expect,” said Lu Zhang, Vice President for Engineered Polymers & Medical Solutions, Lubrizol.

“This new North American distribution agreement adds another layer to the strong, successful distribution partnership IMCD and Lubrizol have enjoyed for many years,” said Jean-Paul Scheepens, President of IMCD US. “We are eager to bring Lubrizol innovation to new customers.”

Company

Logo:

IMCD Group B.V.

Wilhelminaplein 32
3072 Rotterdam
Netherlands

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read